Yorktown Management & Research Co Inc Takes $245,000 Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Yorktown Management & Research Co Inc bought a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 4th quarter, HoldingsChannel reports. The fund bought 6,600 shares of the company’s stock, valued at approximately $245,000.

Several other hedge funds and other institutional investors have also made changes to their positions in AMPH. GAMMA Investing LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after acquiring an additional 273 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after acquiring an additional 398 shares in the last quarter. Asset Management One Co. Ltd. purchased a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $78,000. KBC Group NV boosted its holdings in shares of Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after acquiring an additional 650 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after buying an additional 301 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $33.19 on Wednesday. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.60 billion, a P/E ratio of 11.06, a PEG ratio of 1.07 and a beta of 0.81. The company has a 50-day moving average of $38.89 and a two-hundred day moving average of $43.88. Amphastar Pharmaceuticals, Inc. has a 12-month low of $32.25 and a 12-month high of $56.45.

Wall Street Analyst Weigh In

AMPH has been the topic of a number of research analyst reports. Piper Sandler downgraded shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $66.00 to $36.00 in a report on Tuesday. Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of “Hold” and an average price target of $50.33.

Insiders Place Their Bets

In related news, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $43.77, for a total transaction of $437,700.00. Following the transaction, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This represents a 24.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Rong Zhou sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the transaction, the executive vice president now directly owns 118,469 shares in the company, valued at $5,262,392.98. The trade was a 5.58 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,893 shares of company stock worth $1,329,570. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.